Biocytogen Announces RenLite® Licensing Agreement with Janssen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri Introduces Latest ArcGIS Integrations for Microsoft Fabric19.11.2025 00:05:00 EET | Press release
Esri, the global leader in location intelligence, today announced General Availability of ArcGIS GeoAnalytics for Microsoft Fabric. Also now in public preview is ArcGIS Maps for Microsoft Fabric, a mapping tool enabling users to easily add context with business, lifestyle, demographic, and environmental data to enrich enterprise data in Microsoft OneLake. “This integration makes some of Esri’s core capabilities accessible for data professionals directly from their Microsoft Fabric environment,” said Jack Dangermond, Esri president. “We are pleased to advance our long-standing strategic collaboration with Microsoft to help our shared customers unlock spatial insights and reveal unexplored patterns.” There has been growing market demand among data scientists, data engineers, business analysts, and their executive stakeholders for spatial analytics and mapping. Esri’s GeoAnalytics for Fabric will allow data to flow across an organization, whether working from OneLake, Microsoft Power BI,
Finalists Announced for 2026 SPIE Startup Challenge, Showcasing Innovative, Investment-Ready Optics and Photonics Technologies and Applications18.11.2025 23:05:00 EET | Press release
Sevenearly-stage startup companies have been selected to compete for a top prize of $10,000 at the 16th annual SPIE Startup Challenge at Photonics West on 20 January. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118106028/en/ Eventual winner, Trey Daunis of Max-IR Labs, pitches their innovative technology during the 2025 SPIE Startup Challenge, engaging judges and a packed audience at SPIE Photonics West. The SPIE Startup Challenge is a competitive entrepreneurial platform for new businesses that utilize optics and photonics for innovative products or applications. Participating teams are competing for sponsored prizes, in addition to gaining increased visibility with potential investors and exposure to potential collaborators or partners. Cash prizes of $10,000, $5,000, and $2,500, provided by Startup Challenge Founding Partner Jenoptik, will be awarded to the top three finalists. The SPIE Startup Challenge is also sup
Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit18.11.2025 22:48:00 EET | Press release
At today’s Franco-German Summit on Digital Sovereignty in Berlin, Owkin, together with leading academic partners Gustave Roussy (France) and Charité Comprehensive Cancer Center (Germany), announced a landmark initiative to build the first pan-European agentic infrastructure to make biological data AI-ready, as a key step towards biological super intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118529021/en/ Thomas Clozel (CEO of Owkin) joins Emmanuel Macron, Friedrich Merz and others at the Franco-German Digital Sovereignty Summit The project aims to develop and deploy modern AI methods to support biological research and drug development. An initial focus will be on supporting the harmonization and structuring of biomedical data across Europe to enhance scientific collaboration. It will combine agentic AI systems and cutting-edge biomedical data structuring, to power a new reasoning model capable of automating
Reply at Microsoft Ignite 2025: Showcasing AI Innovation, Copilot Experiences, and Intelligent Enterprise Solutions18.11.2025 22:30:00 EET | Press release
Reply [EXM, STAR: REY] is taking part in Microsoft Ignite 2025, a premier event for technology professionals and decision-makers hosted by Microsoft, held from November 18 to 21 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118836834/en/ A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. With more than 2,000 Microsoft certifications across its network of companies – including Business Elements Reply, Cluster Reply, Solidsoft Reply, Light Reply, Root16 Reply, Valorem Reply, WM Reply and Zest Reply – the group has achieved all six Microsoft Solutions Partner designations. This year, Reply is also celebrating two major h
ClickHouse Strengthens Collaboration with Microsoft through Microsoft OneLake Integration for Seamless Data Interoperability18.11.2025 22:00:00 EET | Press release
ClickHouse Inc., the company behind one of the world’s fastest and most popular real-time analytics databases, today announced the availability of a powerful new integration with Microsoft OneLake, the unified data lake of Microsoft Fabric. This integration enables organizations to harness the scale, governance, and simplicity of OneLake with the speed and flexibility of ClickHouse for real-time, large-scale analytical workloads. Learn more in our technical post. Expanding the ClickHouse-Microsoft collaboration Following the general availability of ClickHouse Cloud on Microsoft Azure, recent performance enhancements of ClickHouse on Azure Blob Storage, and a steady series of new capabilities, this integration with Microsoft OneLake marks the latest milestone in ClickHouse’s growing collaboration with Microsoft. This initiative reinforces ClickHouse’s commitment to deep interoperability across Microsoft’s data ecosystem. From Azure to Fabric, the goal is to enable real-time analytics wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom